Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Global CAR-T Products on the Market and BCMA-Targeted CAR-T Products
Global CAR-T Products on the Market
CAR-T
Globally Approved BCMA-Targeted CAR-T Products
– Multiple Myeloma
Multiple Myeloma
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**
**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**
As an innovative immunotherapy, CAR-T therapy has gradually become available in China in recent years, attracting significant attention from patients. Although it is dubbed the “million-dollar therapy” due to its high cost, experts emphasize that CAR-T is not a conventional drug but a “living drug.” Its effectiveness is confirmed, but the outcome largely depends on the skill and experience of the operator. Like a horse-riding competition, the handler must fully understand and control this “good horse.” Early data show promising results, and while the overall treatment cost remains high, its efficacy is undeniable.
To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Meet Chinese Doctor. Xiaoyan Ke: Leading Expert in Hematology and Lymphoma Treatment
Meet Chinese Doctor. Xiaoyan Ke: Leading Expert in Hematology and Lymphoma Treatment
Global Healthcare
In the journey of treating hematologic malignancies, for patients in advanced stages with no standard clinical treatment options, seeking medical care abroad or through remote video consultations has become a pathway to new hope. Through these means, patients can connect with top international experts and gain access to new treatment plans and more options. Leading international specialists not only continuously achieve breakthroughs in treatment technologies but also provide personalized treatment recommendations based on the latest research. Next, we are proud to introduce a highly acclaimed and renowned expert in the fields of hematology and lymphoma from China—Professor Ke Xiaoyan.
### Expert Profile
**Professor Ke Xiaoyan** is the Chief Physician of the Hematology Department at Peking University Third Hospital and serves as the Lead Expert of the Adult Lymphoma Division at the GoBroad Medical (Hematology) Beijing Research Center. She is also the Deputy Director of the Hematology Department at Peking University Health Science Center. Additionally, she holds the position of Chief Consultant for the Adult Lymphoma Department at Beijing GoBroad-Boren Hospital, where she has trained numerous PhD students, establishing herself as one of China’s top experts in hematologic oncology.
Professor Ke is highly regarded within the Chinese medical community. She has served as the Chairperson of the Hematology Branch of the Chinese Female Physicians Association and currently holds key positions in several authoritative medical organizations. Her academic background and international reputation have earned her wide recognition in the field of hematologic malignancy treatment.
### Areas of Expertise
Professor Ke has extensive experience in the standardized treatment of lymphoma, targeted chemotherapy, and both autologous and allogeneic hematopoietic stem cell transplantation. She is at the forefront of international research in treating relapsed and refractory lymphomas through second-generation gene sequencing, targeted therapies, and CAR-T cell immunotherapy. Beyond her clinical expertise, she is a leading figure in the molecular diagnosis of malignant blood diseases and the monitoring of minimal residual disease.
### Research Contributions and International Reputation
Professor Ke has made remarkable achievements in scientific research as well. She has been the principal investigator in more than 70 international multicenter clinical trials and has published over 300 academic papers, including more than 30 influential SCI papers in top-tier international journals, focusing on cutting-edge research in lymphoma and hematologic malignancies. She has authored and contributed to more than 30 authoritative medical books and received over 40 national research grants, significantly advancing the field of hematology.
In addition to her research work, Professor Ke serves on the editorial boards of several medical journals, including as Deputy Editor-in-Chief of the **Journal of Leukemia & Lymphoma**. She is also a consulting expert for the Ministry of Health and a key member of the Central Health Consultation Committee. As a leading figure in international hematologic oncology research, her studies encompass the molecular mechanisms of lymphoma, immunotherapy, and stem cell transplantation, enhancing China’s standing in global academic research.
### Main Research Focuses
– Standardized treatment of lymphoma
– Molecular diagnosis of malignant blood diseases and monitoring of minimal residual disease
– Research on autologous peripheral blood stem cell transplantation for malignant blood diseases
– Non-myeloablative transplantation and CAR-T cell therapy for refractory relapsed malignant lymphoma
– Research on B7/CD28 signaling and T-cell immune tolerance mechanisms
– Study of the molecular mechanisms of tumor immunity
### Publications and Research Achievements
Professor Ke Xiaoyan has authored several authoritative books in the field of lymphoma, including **Lymphoma** and **Lymphoma Diagnosis and Treatment Manual**. Her key SCI papers include:
-
**Biological and Clinical Influences of NPM1 in AML Patients with DNMT3A Mutations**, *Cancer Management and Research*, 2018.
-
**Clinical and Biological Implications of IDH1/2 in AML with DNMT3A Mutation**, *Cancer Management and Research*, 2018.
-
**High PD-L1 Expression Predicts Poor Prognosis in Diffuse Large B-cell Lymphoma**, *Annals of Hematology*, 2018.
-
**Molecular Predictors of Post-transplant Survival in Acute Myeloid Leukemia**, *Blood Cancer Journal*, 2017.
-
**High Expression of CPNE3 Predicts Adverse Prognosis in AML**, *Cancer Science*, 2017.
-
**High Expression of ETS2 Predicts Poor Prognosis in AML**, *Journal of Translational Medicine*, 2017.
-
**A Minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 Contributes to Leukemogenesis in t(8;21) AML**, *International Journal of Cancer*, 2017.
### Online Consultation and Appointment Information
Professor Ke currently offers online video consultation services. Patients can make appointments through the following methods:
WhatsApp: Https://wa.me/+8613717959070
Wechat：doctors0152
Email: doctor.huang@globecancer.com
#Hematology #LymphomaTreatment #AdvancedCancerCare #InternationalConsultation #CAR_TTherapy #PersonalizedMedicine #ProfessorKeXiaoyan #StemCellTransplantation #CancerResearch #GlobalHealthcare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**
**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**
patient story
In the long journey of life, cancer often strikes like a sudden storm, leaving patients and their families devastated. Mrs. Li, a young and resilient mother from China, was no exception. Two years ago, she was diagnosed with relapsed and refractory B-cell non-Hodgkin lymphoma. The shocking news felt like a bolt from the blue, throwing her once-happy family into the depths of despair.
Traditional chemotherapy and radiation therapy once brought a flicker of hope for Mrs. Li, temporarily alleviating her condition. However, fate seemed to play a cruel trick on her again, as the tumor returned with more aggression, no longer responding to conventional treatments. The repeated rounds of therapy took a toll on her body and spirit. Both Mrs. Li and her family were pushed to the brink of collapse, feeling trapped in a deep abyss with no light of hope in sight.
Just when Mrs. Li was about to give up, fate intervened. Thanks to the relentless efforts of the “Advanced Medicine in China” team, they successfully connected Mrs. Li with the country’s top hematology specialists. After a series of communications and coordination, this expert became her last lifeline, taking on the responsibility of devising the best treatment plan during her darkest hours.
After conducting a comprehensive and detailed examination of Mrs. Li, the expert, relying on extensive experience and professional judgment, decisively recommended CAR-T therapy, a cutting-edge treatment. This innovative immunotherapy acts like a magical key, reactivating the patient’s immune system to precisely target and attack cancer cells, offering a new glimmer of life. Faced with this final hope, Mrs. Li carefully considered her options and bravely decided to seize it, determined to fight once more for her life.
The results were truly remarkable. CAR-T therapy produced astonishing effects in Mrs. Li, like a dazzling light in the darkness. After just a few weeks, follow-up tests showed that her tumor had significantly shrunk, and the symptoms that had once plagued her improved dramatically. This was a pivotal moment, allowing Mrs. Li and her family to rediscover hope for the future.
In the months that followed, under close monitoring and consolidation treatment, Mrs. Li’s condition stabilized, as though the ferocious beast of cancer had been tamed. Ultimately, she achieved a miracle—her cancer reached complete remission. For Mrs. Li and her family, this was nothing short of extraordinary, filling their hearts with overwhelming joy and gratitude. They were not only rekindled with the flame of hope for life but also deeply thankful to the “Advanced Medicine in China” team and CAR-T therapy.
As the recommending team, “Advanced Medicine in China” feels honored to have witnessed Mrs. Li’s recovery journey. This is not just a victory for one patient but a successful step forward in the ongoing battle against cancer, inspiring the team to continue seeking rays of hope for more patients. Mrs. Li’s story has become a powerful tale of triumph, spreading rapidly among fellow patients. Her courage and perseverance have set an example for many others bravely fighting blood cancer, encouraging them to press on and never give up.
Through Mrs. Li’s case, CAR-T therapy in China has once again demonstrated its immense potential in the treatment of lymphoma. Like a rising star, it is bringing new hope to blood cancer patients worldwide, illuminating their path toward overcoming the disease. In the future, CAR-T therapy in China will undoubtedly create more miracles, offering patients the dawn of life and a brighter future.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#patientstory #CARTTherapy #CancerSurvivor #Lymphoma #LymphomaTreatment #BloodCancerAwareness#MedicalMiracles #ChinasMedicalAdvances #CancerResearch #PatientStories #HopeAgainstCancer #Immunotherapy #FightCancer #CancerRemission #CourageToFight #BreakthroughInMedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting
**China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting**
CSCO
#CSCO #CSCO2024 #Lymphoma #CART #LBCL #RRLBCL #ChinaCAR-T
At the 27th Annual Chinese Society of Clinical Oncology (CSCO) Conference, held in Xiamen, China, CAR-T therapy took center stage as a key focus for the treatment of large B-cell lymphoma (LBCL). As a Chimeric Antigen Receptor T-cell (CAR-T) therapy, this innovative approach is revolutionizing the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), offering new hope for patients where traditional therapies have been less effective.
### Breakthroughs in CAR-T Therapy for LBCL
As a major innovation in immunotherapy, CAR-T therapy has shown remarkable efficacy in treating R/R LBCL. Clinical data indicates that about one-third of R/R LBCL patients can achieve long-term remission or even cure through CAR-T therapy. Notably, Axicabtagene ciloleucel (Axi-cel), developed by Fosun Kite Biotechnology, is the first domestically approved CD19-targeted autologous CAR-T product in China. Six-year follow-up results revealed that the two-year overall survival rate was 50.5%, and the six-year lymphoma event-free survival rate was 33.5%.
Meanwhile, Relma-cel, a CAR-T product independently developed by JW Therapeutics in China, has also achieved impressive results. Two-year follow-up data showed a median duration of response of 20.3 months, further highlighting China’s growing research and manufacturing strength in the CAR-T therapy field.
### CAR-T Therapy Expands from Third-Line to Second-Line Use
While CAR-T therapy was initially used only for patients who had failed multiple lines of treatment, it is now being increasingly applied in second-line settings. Recent studies have shown that CAR-T therapy outperforms traditional high-dose chemotherapy and autologous stem cell transplant (ASCT) in certain patient groups. For example, the ZUMA-7 study demonstrated that Axi-cel significantly improved event-free survival (EFS) for LBCL patients treated in the second-line setting, with a median EFS of 8.3 months, compared to 2 months in the ASCT group.
As more research progresses, CAR-T therapy has been recommended by leading clinical guidelines, such as the National Comprehensive Cancer Network (NCCN), for use in patients with primary refractory or early relapsing LBCL. This shift underscores CAR-T’s growing role in earlier stages of treatment, providing more therapeutic options for patients.
### Challenges and Future Prospects
In the exploration of CAR-T as a first-line treatment, promising results are beginning to emerge. The ZUMA-12 study evaluated the use of Axi-cel in high-risk LBCL patients in the first-line setting, with a three-year follow-up showing an overall survival rate of 90.6%. These findings suggest that CAR-T therapy could become an important treatment option for high-risk patients even in the first-line setting.
### China’s Leading Role in CAR-T Therapy
China is rapidly emerging as a global leader in the development and commercialization of CAR-T therapy. With domestically developed products like Axi-cel and Relma-cel achieving significant progress both in China and globally, China’s competitive edge in this field is becoming increasingly evident. As the technology matures and more clinical data are released, the future of CAR-T therapy in LBCL treatment looks exceptionally bright.
The 2024 CSCO Annual Meeting showcased China’s strong commitment to advancing CAR-T therapy. As breakthroughs and challenges coexist, CAR-T therapy is poised to continue playing a critical role in the treatment of large B-cell lymphoma, with China leading the way in this global medical revolution.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#LymphomaTreatment #ImmunotherapyRevolution #CancerResearch #MedicalInnovation #BCellLymphoma
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The significance of the 11 CD19 and BCMA CAR-T therapies currently approvedin China and the U.S. forpatients with hematologic malignancies.
The significance of the 11 CD19 and BCMA CAR-T therapies currently approvedin China and the U.S. forpatients with hematologic malignancies.
目前中美上市的11款CD19和BCMA CAR-T对血液瘤患者的意义
Expert：
**Jing Pan**
**Associate Chief Physician**
**Department of Pediatric Hematology, Beijing Gaobo Hospital**
**Professional Memberships:**
– Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association
– Youth Committee Member, Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association
– Youth Committee Member, Clinical Application Professional Committee of the Chinese Medical Biotechnology Association
**Expertise:**
Dr. Pan currently manages an 80-bed pediatric hematology unit and has extensive experience in pediatric hematology, particularly in CAR-T cell immunotherapy, with nearly 10 years of experience in the field. She is dedicated to stratified CAR-T treatment, optimizing the management of complications during CAR-T therapy, and establishing an efficacy monitoring system post-treatment. Dr. Pan and her team have accumulated one of the largest single-center case collections globally, particularly in the areas of sequential CAR-T therapy for improving long-term outcomes in B-ALL and in exploring autologous and allogeneic CD5, CD7 CAR-T therapy for T-ALL/LBL.
Her related clinical research on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and CD19-22 sequential CAR-T has been published in leading international journals such as *Lancet Oncology*, *JCO*, *Blood*, *JHO*, and *Leukemia*. Additionally, she has frequently presented the latest advancements in her team’s immunotherapy research at both domestic and international conferences, including ASCO, ASH, EHA, and JSH.
潘 静
副主任医师
北京高博医院 小儿血液科
中国抗癌协会小儿肿瘤专业委员会专业委员
中国抗癌协会血液肿瘤专业委员会青年委员
中国医药生物技术协会医药生物技术临床应用专业委员会青年委员
擅长:
目前独立管理床位数80张的儿童血液病区。从事儿童血液科临床工作多年，特别是在儿童CAR-T细胞免疫治疗方面积累了近10年的经验。致力于CAR-T的分层治疗，优化CAR-T治疗过程中的并发症处理，建立CAR-T治疗后的疗效监控体系。尤其是其带领团队在序贯CAR-T提高B-ALL远期预后，T-ALL/LBL的自体、异体CD5、CD7CAR-T治疗探索方面目前积累了全球较大的单中心病例数。相关的CD7CAR-T临床研究、CD19CAR-T临床研究、CD22CAR-T临床研究、CD19-22序贯CAR-T研究等，发表在国际血液病权威杂志期刊Lancet on-cology、JC0、Blood、JHO和Leukemia。并多次在国内外学术会议(美国临床肿瘤大会ASCO、美国血液年会ASH、欧洲血液年会EHA、日本血液年会JSH)汇报团队免疫治疗的最新进展。
To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The Courage to Be First: China’s CAR-T Pioneer, “Emily of China,” Celebrates 6 Years in Complete Remission!
### The Courage to Be First: China’s CAR-T Pioneer, “Emily of China,” Celebrates 6 Years in Complete Remission!
Patient Story
#CART #PatientStory #lymphoma #TP53 #DLBCL #CARTTherapy
Meet Mrs. Qin, a true fighter and the first brave patient in China to receive Fosun Kite’s Axicabtagene Ciloleucel in a CAR-T clinical trial. Her story is one of hope, perseverance, and the power of innovation.
In early 2017, a routine check-up uncovered a small lump in her neck, leading to a diagnosis of diffuse large B-cell lymphoma (DLBCL) with a TP53 gene mutation—a high-risk condition. After enduring 12 rounds of grueling chemotherapy, the cancer still returned. Just when hope seemed to be fading, Mrs. Qin became the first patient in China to join a groundbreaking CAR-T therapy trial at Ruijin Hospital under the care of Dr. Zhao Weili. She was a pioneer, much like Emily Whitehead in the U.S., the world’s first pediatric patient to receive CAR-T therapy.
Mrs. Qin recalls the challenging days of her treatment, which involved high fevers and fatigue, yet the unwavering support of Dr. Zhao’s team helped her push through. The cutting-edge CAR-T treatment not only controlled the tumor but led her into complete remission. Six years later, she remains cancer-free and now serves as a volunteer at the hospital, inspiring others who are fighting the same battle.
During the first “CAR-T Therapy Survivor Conference” in Wuhan of China, Mrs. Qin took the stage to share her emotional journey. Her story moved everyone in attendance, from fellow patients to medical experts, as she expressed gratitude for the love and care she received. “Ruijin Hospital is not just where I found a new lease on life, but a home filled with compassion and world-class medical expertise,” she shared.
Mrs. Qin’s tale of courage is a beacon of hope for those still battling the disease. Her message is simple: “No matter how tough the road, never lose faith. After every storm, the rainbow will appear.”
🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#ChinaCAR-T #CAR-TTherapy #CancerSurvivor #MedicalBreakthrough #FosunKite #DLBCL #CancerRemission #InnovativeMedicine #HopeHealing #RuijinHospital #ChineseMedicalPioneers #PatientStories #EmilyofChina
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Can the Million-dollar Anti-cancer Injection “Cure” Tumors?
Can the Million-dollar Anti-cancer Injection “Cure” Tumors?
Is CAR-T therapy really a “one-shot cure”?
And how can we ensure that this CAR “drives well and drives long”?
百万抗癌针能“治愈”肿瘤吗?
如何让CAR“开得好，开得久?”
Expert：
**Jing Pan**
**Associate Chief Physician**
**Department of Pediatric Hematology, Beijing Gaobo Hospital**
**Professional Memberships:**
– Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association
– Youth Committee Member, Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association
– Youth Committee Member, Clinical Application Professional Committee of the Chinese Medical Biotechnology Association
**Expertise:**
Dr. Pan currently manages an 80-bed pediatric hematology unit and has extensive experience in pediatric hematology, particularly in CAR-T cell immunotherapy, with nearly 10 years of experience in the field. She is dedicated to stratified CAR-T treatment, optimizing the management of complications during CAR-T therapy, and establishing an efficacy monitoring system post-treatment. Dr. Pan and her team have accumulated one of the largest single-center case collections globally, particularly in the areas of sequential CAR-T therapy for improving long-term outcomes in B-ALL and in exploring autologous and allogeneic CD5, CD7 CAR-T therapy for T-ALL/LBL.
Her related clinical research on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and CD19-22 sequential CAR-T has been published in leading international journals such as *Lancet Oncology*, *JCO*, *Blood*, *JHO*, and *Leukemia*. Additionally, she has frequently presented the latest advancements in her team’s immunotherapy research at both domestic and international conferences, including ASCO, ASH, EHA, and JSH.
潘 静
副主任医师
北京高博医院 小儿血液科
中国抗癌协会小儿肿瘤专业委员会专业委员
中国抗癌协会血液肿瘤专业委员会青年委员
中国医药生物技术协会医药生物技术临床应用专业委员会青年委员
擅长:
目前独立管理床位数80张的儿童血液病区。从事儿童血液科临床工作多年，特别是在儿童CAR-T细胞免疫治疗方面积累了近10年的经验。致力于CAR-T的分层治疗，优化CAR-T治疗过程中的并发症处理，建立CAR-T治疗后的疗效监控体系。尤其是其带领团队在序贯CAR-T提高B-ALL远期预后，T-ALL/LBL的自体、异体CD5、CD7CAR-T治疗探索方面目前积累了全球较大的单中心病例数。相关的CD7CAR-T临床研究、CD19CAR-T临床研究、CD22CAR-T临床研究、CD19-22序贯CAR-T研究等，发表在国际血液病权威杂志期刊Lancet on-cology、JC0、Blood、JHO和Leukemia。并多次在国内外学术会议(美国临床肿瘤大会ASCO、美国血液年会ASH、欧洲血液年会EHA、日本血液年会JSH)汇报团队免疫治疗的最新进展。
To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Hematologic Tumors – Detection: Unveiling the Mysteries of the Disease
**
Hematologic Tumors** – 
Detection:
Unveiling the Mysteries of the Disease
Hematologic tumors are a group of malignant diseases caused by the abnormal proliferation of blood-forming cells, affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic tumors include leukemia, myelodysplastic syndromes, lymphoma, multiple myeloma, and myeloproliferative neoplasms.
### Causes of Hematologic Tumors
The development of hematologic tumors is highly complex. Key factors include genetic mutations, immune system abnormalities, radiation exposure, contact with harmful chemicals, viral infections, and hereditary factors. Additionally, unhealthy lifestyle habits, prolonged psychological stress, and poor environmental conditions can increase the risk of these diseases.
In recent years, due to global population aging and modern lifestyle changes, the incidence of hematologic tumors has been on the rise. In China, leukemia and lymphoma rank among the top malignant tumors in terms of incidence and mortality. Therefore, early detection and accurate diagnosis of hematologic tumors are crucial for improving patient outcomes.
### Detection Methods for Hematologic Tumors
Since early symptoms of hematologic tumors are often subtle, many patients are diagnosed in the late stages of the disease. Thus, early detection is essential. The medical field has developed a variety of advanced and precise diagnostic methods to detect and confirm hematologic tumors.
#### 1. **Blood Tests**
A complete blood count (CBC) is a fundamental tool for detecting hematologic tumors. By analyzing the quantity and morphology of red blood cells, white blood cells, and platelets, physicians can preliminarily identify abnormalities. For example, leukemia patients often exhibit abnormal increases or decreases in white blood cells, along with immature cells in the bloodstream.
#### 2. **Bone Marrow Biopsy**
Bone marrow biopsy is a key diagnostic method for hematologic tumors. By analyzing the hematopoietic cells from a bone marrow sample, physicians can determine the presence of abnormal or malignant cell proliferation. This procedure not only confirms the type of hematologic tumor but also helps assess disease progression and treatment efficacy.
#### 3. **Flow Cytometry**
Flow cytometry is an efficient method for detecting hematologic tumors. It rapidly analyzes characteristic markers on the surface of cells, helping doctors identify and quantify abnormal cells. It plays an essential role in diagnosing diseases such as leukemia and lymphoma.
#### 4. **Genetic Testing**
Genetic mutations are a critical factor in many hematologic tumors. Genetic testing can reveal the mutation profile within a patient’s cells, enabling doctors to better understand the underlying cause of the disease and formulate personalized treatment plans. With advancements in molecular biology, genetic testing has become a cornerstone of precision medicine.
#### 5. **Imaging Tests**
For certain aggressive hematologic tumors, imaging tests like CT, PET-CT, and MRI help doctors assess the extent and spread of the disease. These techniques are particularly valuable in staging and evaluating the treatment response of lymphomas.
### Conclusion
The detection of hematologic tumors has become increasingly accurate, greatly improving early diagnosis rates and treatment outcomes. By effectively utilizing blood tests, bone marrow biopsies, flow cytometry, genetic testing, and imaging, patients can receive earlier diagnoses and more tailored treatment plans. With continuous advances in medical technology, the cure rates for hematologic tumors are expected to rise, bringing hope for better health to more patients.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp:+8613717959070
（Https://wa.me/+8613717959070）
Email: doctor.huang@globecancer.com
#HematologicCancer #BloodCancer #CancerDetection #LeukemiaAwareness #LymphomaAwareness #MultipleMyeloma #CancerDiagnosis #GeneticTesting #EarlyDetection #FlowCytometry #BoneMarrowBiopsy #CancerResearch #PrecisionMedicine #CancerTreatment #Immunotherapy #Oncology #CancerAwareness #HealthInnovation #MedicalAdvancements #CancerCare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)
CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)
MCL
#MantleCellLymphoma #MCL #Lymphoma #RRMCL #RelmaCel #CART #Non-HodgkinLymphoma #NHL
In the global cancer treatment landscape, the advancements in CAR-T cell therapy are remarkable, particularly in the treatment of relapsed and refractory Mantle Cell Lymphoma (MCL). China’s CAR-T therapy, Relma-cel, has emerged as a new beacon of hope for patients, delivering deep and lasting remission for those who have undergone multiple lines of treatment.
Mantle Cell Lymphoma: A Complex and Challenging Disease
Mantle Cell Lymphoma (MCL) is a subtype of Non-Hodgkin Lymphoma (NHL) originating from B cells, accounting for 6% to 8% of all NHL cases. The disease typically affects older adults, and most patients are diagnosed at an advanced stage with poor prognostic factors. Despite the availability of various treatments, including Bruton’s Tyrosine Kinase inhibitors (BTKi), MCL remains difficult to cure, and patients often face recurrence or progression of the disease.
Relma-cel: A New Hope for Relapsed/Refractory MCL
In China, Relma-cel, a novel CAR-T cell therapy, was approved by the National Medical Products Administration (NMPA) in August 2024 for the treatment of adult patients with relapsed or refractory MCL who have failed multiple lines of therapy. This therapy offers a groundbreaking treatment option for MCL patients.
A Case Study: Deep Remission Achieved with CAR-T Therapy
A 51-year-old male MCL patient, after multiple treatment failures, eventually achieved complete remission through the CAR-T therapy Relma-cel. Diagnosed in 2014, the patient underwent R-CHOP chemotherapy, Rituximab-targeted therapy, as well as BTKi and PI3K inhibitor treatments. However, the disease continued to relapse with poor prognosis. Finally, in 2022, the patient achieved deep and lasting remission through CAR-T therapy. After CAR-T cell infusion, the patient reached complete remission within just one month and remained in remission for 22 months of follow-up.
Expert Commentary: The Future of CAR-T Therapy
Professor Li Ping from Tongji Hospital, Tongji University, highlighted that CAR-T cell therapy has broken through the limitations of traditional treatments for relapsed/refractory MCL, offering new hope for high-risk patients. For those who cannot benefit from conventional treatments, the introduction of CAR-T therapy is crucial, especially when applied early in the frontline treatment stage to maximize its efficacy.
Based on the latest clinical research data, Relma-cel has shown encouraging complete remission rates (67.8%) and objective response rates (81.36%) in treating relapsed/refractory MCL patients. These findings further underscore the importance of CAR-T cell therapy in patients who have failed BTKi treatment, positioning it as a potential first-choice treatment for these patients.
Globally, CAR-T therapy has become a standard treatment for relapsed/refractory MCL, particularly in third-line treatment settings. For patients with poor prognostic factors, CAR-T therapy may be key to overcoming the limitations of traditional treatments and extending survival.
Conclusion
As CAR-T cell therapy continues to evolve, more patients with relapsed/refractory MCL will have the opportunity to benefit from it. The clinical application of Relma-cel not only brings deep and lasting remission to patients but also sets a new example for the development of CAR-T therapy worldwide. With early intervention and precise treatment strategies, CAR-T therapy has the potential to create a brighter future for MCL patients.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
（Https://wa.me/+8613717959070）
Email: doctor.huang@globecancer.com
#CAR_T #CancerTreatment #RelmaCel #MCL #LymphomaAwareness #Oncology #Immunotherapy #MedicalInnovation #CancerResearch #ChinaHealthcare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**China’s CAR-T Therapy Approved for New Indication: Bringing New Hope to Relapsed Mantle Cell Lymphoma Patients**
**China’s CAR-T Therapy Approved for New Indication: Bringing New Hope to Relapsed Mantle Cell Lymphoma Patients**
MCL
The approval of Relmacabtagene Autoleucel brings renewed hope for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL). MCL is a rare and aggressive subtype of non-Hodgkin lymphoma (NHL). Despite advancements in treatment options over recent years, patients with R/R MCL continue to face high relapse rates and poor prognoses. Therefore, there is an urgent need for more effective and innovative therapies to improve treatment outcomes and survival expectations for these patients.
Relmacabtagene, a CD19-targeted autologous CAR-T cell therapy, works by precisely targeting and attacking cancerous B cells. It has shown remarkable efficacy in clinical studies. On August 27, 2024, the National Medical Products Administration (NMPA) officially approved the new indication for Relmacabtagene, allowing its use in adult patients with relapsed or refractory mantle cell lymphoma who have undergone at least two prior systemic therapies, including Bruton tyrosine kinase inhibitors (BTKi). This approval marks another significant milestone following Relmacabtagene’s previous approvals for R/R large B-cell lymphoma (LBCL) and follicular lymphoma (FL).
The treatment of R/R MCL has always been challenging. Traditional therapies often yield limited long-term results, particularly for patients who have failed BTKi treatment, leaving them with fewer options. The emergence of Relmacabtagene offers a new treatment avenue for these patients. Clinical studies demonstrate that this CAR-T cell therapy can significantly extend progression-free survival (PFS) and overall survival (OS), with a favorable safety profile.
The approval of this new indication not only expands the use of Relmacabtagene in treating R/R MCL but also paves the way for future advancements in MCL treatment. The application of CAR-T cell therapy, especially in high-risk patients, has shown potential in overcoming aggressive lymphomas. For patients with complex genetic characteristics and challenging treatment profiles, Relmacabtagene is undoubtedly a powerful therapeutic option.
Looking ahead, Relmacabtagene is expected to benefit more R/R MCL patients in clinical practice, pushing the boundaries of treatment in this field. As research deepens and new therapies continue to emerge, Relmacabtagene is poised to play an increasingly important role in improving patient outcomes and extending survival, offering new hope to R/R MCL patients worldwide.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in Chinafor preliminary evaluation!
WhatsApp: +86137 1795 9070
(Http://wa.me/+8613717959070)
Email: doctor.huang@globecancer.com
#BloodCancerTreatment #CAR_TCellTherapy #CancerBreakthrough #Immunotherapy #BCMACART #MedicalAdvancements #CancerSurvivorship #ChinaMedicalInnovation #MCL #RRMCL #HopeForCancerPatients #Relmacabtagene #MCLTreatment #CancerBreakthrough #ChinaApproval #CAR_TCellTherapy #LymphomaTreatment #CancerInnovation #HematologyAdvances
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Medical Team Research: 64.6% Complete Remission Rate, Over Half of Patients Progression-Free for More Than Two Years! Targeted Therapy Combined with Chemotherapy is Safe and Effective as First-Line Treatment for Lymphoma
**Chinese Medical Team Research: 64.6% Complete Remission Rate, Over Half of Patients Progression-Free for More Than Two Years! Targeted Therapy Combined with Chemotherapy is Safe and Effective as First-Line Treatment for Lymphoma**
Lymphoma